Genotype-Guided NAC Therapy for Idiopathic Pulmonary Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) using N-acetylcysteine (NAC) are ineffective for all patients, and previous reports indicate potential harm for certain genetic subgroups, highlighting the need for personalized therapeutic approaches based on genetic profiling.
Innovation Solution
Genotyping patients for specific single nucleotide polymorphisms (SNPs) in the TOLLIP and MUC5B genes to determine the efficacy and safety of NAC or combination therapies, such as PAN (prednisone, azathioprine, and NAC), allowing for tailored treatment strategies that benefit some patients while avoiding harmful outcomes in others.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NAC therapy is administered to all IPF patients, then some patients may benefit from antioxidant effects, but certain genetic subgroups experience increased risk of death and adverse outcomes
Solution Approach 1:
The patent applies local quality by tailoring the therapeutic intervention to specific genetic subgroups. Patients are stratified based on their TOLLIP and MUC5B genotypes, with NAC therapy recommended only for those with beneficial genotypes (e.g., TOLLIP TT genotype) and contraindicated for those with harmful genotypes (e.g., TOLLIP CC genotype). This personalized approach ensures that the therapy's beneficial antioxidant effects are targeted to patients who will respond positively while avoiding harm to genetically susceptible individuals.
Solution Approach 2:
The patent changes the parameter of treatment decision-making from a uniform approach to a genotype-stratified approach. By incorporating genetic testing results into the therapeutic decision process, the patent transforms the treatment parameter based on individual patient genetics, allowing clinicians to adjust therapy recommendations according to the patient's specific genetic profile and predicted response to NAC.
2Reliability
If genotype testing is performed to guide NAC therapy, then treatment efficacy is improved for specific patient groups, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent segments the IPF patient population into distinct genetic subgroups based on TOLLIP and MUC5B genotypes. This segmentation allows for simplified treatment algorithms within each subgroup, where patients with beneficial genotypes receive NAC therapy and those with harmful genotypes avoid it. The segmentation approach transforms a complex decision-making process into a series of simpler, genotype-specific guidelines.
Solution Approach 2:
The patent implements preliminary action by performing genotype testing before initiating NAC therapy. This advance genetic characterization allows clinicians to predict patient response to NAC and make informed treatment decisions before therapy begins, preventing adverse outcomes in patients who would not benefit from the treatment.
Data Source
Figure 1~2
Figure 3A~3B
Figure 4
AI summary
Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.